Viewing Study NCT02520427

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 5:12 AM
Ignite Modification Date: 2026-02-24 @ 10:15 AM
Study NCT ID: NCT02520427
Status: TERMINATED
Last Update Posted: 2024-07-31
First Post: 2015-06-17
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
Sponsor: Amgen
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed/Refractory AML View
None Minimal Residual Disease Positive AML View
None Myelodysplastic Syndrome View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Amgen View
None Phase 1 View
None Clinical Trial View
None Oncology/Hematology View
None Relapsed/Refractory AML View
None Immunotherapy View